Viewing Study NCT05999968


Ignite Creation Date: 2025-12-24 @ 5:39 PM
Ignite Modification Date: 2026-01-05 @ 6:11 PM
Study NCT ID: NCT05999968
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-09
First Post: 2023-08-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Sponsor: Eli Lilly and Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module